マウス実験結核症に対するRifampicinの抗結核作用に関する研究

概要

論文の詳細を見る
Some reports have been presented on the effect of Rifampicin (RFP) for the experimental tuberculosis of mice, but few has been reported on Rifamycin-SV and desacetylrifampiein (Da-RFP). As the significant blood concentration of RFP is kept for a relatively long time, it is expected that RFP might be used on intermittent basis. In the present study, the survival rate of tu b erculous mice was compared among groups receiving oral administration of each drug (RFP, Da-RFP, Rifamycin-SV), and the effect of intermittent treatment by RFP was studied in comparison with that by INH. In the first experiment, the effect of RFP, Da-RFP and Rifamycin-SV was compared. Male mice of dd strain weighing about 25 g were used, and 0.1 ml (1 mg) of bacillary suspension (10 mg/ml) prepared from Sauton culture of Kurono strain was inoculated into tail vein of each mouse. Mice were divided into the following four groups. Each group consists of 9 or 10 mice. Group 1: Non-treated control Group 2: Treated with R F P, 0.5 mg every day orally Group 3: Treated with Da-RFP, 0.5 mg every d a y o rally Group 4: Treated with Rifamycin-SV, 0.5 mg every day orally Treatment was begun from sixth day after challenge, and was con t i nued for twenty days. Thereafter, no treatment was given and they were observed till forty-eighth day to know the survival rate of each group. Result is shown in Fig. All mice were dead till 25 th day in non-treated group and till 27 th day in Rifamycin-SV group, while 37% of mice survival till 48 th day in Da-RFP treated group, and all mice treated with RFP were alive till 48 th day. In the second experiment, the intermittent treatment of RFP was compared with that of INH. Male mice of dd strain weighing about 25 g were used, and 0.01 mg of bacillary suspension prepared from lyophilized bacilli of Kurono strain was inoculated in tail vein of mice. Mice were divided into nine groups. Group 1: Non-treated control Group 2: RFP 0.33 mg (17 mg/kg) every day orally Group 3: RFP 1 mg (50 mg/kg) twice a week orally Group 4: RFP 1 mg (50 mg/kg) once a week orally Group 5: RFP 2 mg (100 mg/kg) once a week orally Group 6: INII 0.2 mg (10 mg/kg) every day orally Group 7: INII 0.6 mg ( 30 mg/kg) twice a wee korally Group 8: INII 0.6 mg (30 mg/kg) once a week orally Group 9: INII 1, 2 mg (60 mg/kg) once a week orally
日本結核病学会の論文

マウス実験結核症に対するRifampicinの抗結核作用に関する研究

スポンサーリンク

概要

著者

関連論文

スポンサーリンク